Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model

Clinical Cancer Research

Volumn 13, Issue 18, 2007, Pages 5488-5496

  Christov, Konstantin ^a   Grubbs, Clinton J ^b   Shilkaitis, Anne ^a   Juliana, M Margaret ^b   Lubet, Ronald A ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; ALITRETINOIN; ARYLBUTYRIC ACID DERIVATIVE; ASCORBIC ACID; BETA NAPHTHOFLAVONE; BEXAROTENE; BROXURIDINE; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DIINDOYLMETHANE; DRUG METABOLIZING ENZYME; GEFITINIB; HORMONE RECEPTOR STIMULATING AGENT; MECLOZINE; METHYLNITROSOUREA; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RETINOID X RECEPTOR; SULINDAC; TAMOXIFEN; TIPIFARNIB; UAB 30; UNCLASSIFIED DRUG; VOROZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER SIZE; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIETARY INTAKE; DRUG EFFICACY; FEEDING; FEMALE; LONG TERM CARE; NICK END LABELING; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; RAT; SHORT COURSE THERAPY; TREATMENT DURATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL MARKERS; CELL PROLIFERATION; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; RATS; RATS, SPRAGUE-DAWLEY;

EID: 34848870968     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0404     Document Type: Article

References (35)

1. Gulliano PM, Pettigrew HM, Grantham FH. N-Nitrosomethylurea as mammary gland carcinogen in rats. J Natl Cancer Inst 1975;54:401-14.
2. Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, van Zwieten MJ. Comparative study of human and rat mammary tumorigenesis. Lab Invest 1990;62:244-78.
3. Russo J, Russo IH. Atlas and histologic classification of tumors of the rat mammary gland. J Mammary Gland Biol Neoplaisa 2000;5:187-200.
4. Chan MM, Lu X, Merchant FM, Inglehart JD, Miron PL. Gene expression profiling of MNU-induced rat mammary tumors: cross species comparison with human breast cancer. Carcinogenesis 2005;26:1343-53.
5. Grubbs CJ, Peckham JC, McDonnough KD. Effect of ovarian hormones on the induction of 1-methyl-1-nitrosourea induced mammary cancer. Carcinogenesis 1983;4:495-7.
6. Anzano MA, Byers SW, Smith JM, et al. Prevention of breast cancer in the rat with 9-cis retionic acid as a single agent and in combination with tamoxifen. Cancer Res 1994;54:4614-7.
7. Suh N, Lamph WW, Glasebrook AL, et al. Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid LG 100268. Clin Cancer Res 2002;8:3270-5.
8. Lubet RA, Steele VE, DeCoster R, et al. Chemopreventive effects of the aromatase inhibitor vorozole (R83842) in the methylnitrosourea-induced mammary cancer model. Carcinogenesis 1998;19:1345-51.
9. Grubbs CJ, Hill DL, McDonough KC, Peckham JC. Methylnitrosourea-induced mammary carcinogenesis: effect of pregnancy on preneoplastic cells. J Natl Cancer Inst 1983;71:625-8.
10. Lubet RA, Steele VE, Casebolt TL, Eto I, Kelloff GJ, Grubbs CJ. Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-OH androstenedione in the MNU-induced mammary tumor model in Sprague Dawley rats. Carcinogenesis 1994;15:2775-80.
11. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA. Chemoprevention of mammary carcinoma by LGD 1069 (Targretin): an RXR selective ligand. Cancer Res 1996;56:5566-70.
12. Lubet RA, Christov K, Nunez N, et al. Efficacy of Targretin on methylnitrosourea induced mammary cancers: prevention and therapy dose response curves and effects on proliferation and apoptosis. Carcinogenesis 2005;26:441-8.
13. Lubet RA, Gordon GB, Prough RA, et al. Modulation of methylnitrosourea- induced breast cancer in Sprague Dawley rats by dehydroepiandrosterone: dose dependent inhibition, effects of limited exposure, effects on peroxisomal enzymes, and lack of effects on levels of Ha Ras mutations. Cancer Res 1998;58:921-6.
14. Lubet RA, Christov K, You M, et al. Effects of the farnesyl transferase inhibitor R115777 (ZARNESTRA) on mammary carcinogenesis: prevention, therapy, and role of H-Ras mutations. Mol Cancer Ther 2006;5:1073-8.
15. Yao R, Wang Y, Lu Y, et al. Efficacy of the farnesyltransferase inhibitor R115777 in a rat mammary tumor model: role of HaRas mutations and use of microarray analysis in identifying potential targets. Carcinogenesis 2006;7:1420-31.
16. Harris RF, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000;15:2101-3.
17. Hickman JA. Apoptosis induced by anti-cancer drugs. Cancer Metastasis Rev 1992;11:121-9.
18. Huovinen R, Warri A, Collan Y. Mitotic activity, apoptosis, and TRPM-2 mRNA expression in DMBA-induced rat mammary carcinoma treated with the antiestrogen toremifene. Int J Cancer 1993;55:685-91.
19. Christov K, Shilkaitis A, Green A, et al. Cellular responses of mammary carcinomas to aromatase inhibitors: effect of vorozole. Breast Cancer Res Treat 2000;60:117-28.
20. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005;23:7212-20.
21. Beresford MJ, Wilson GD, Makris A. Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res 2006;8:216-22.
22. Railo M, Lundin J, Haglund C, von Smitten K, Nordling S. Ki-67, p53, ER receptors, ploidy and S phase as long-termpr ognostic factors in T1 node-negative breast cancer. Tumour Biol 2006;1:45-51.
23. Fabian CJ, Kimler BF, Anderson J, et al. Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. Clin Cancer Res 2004;15:5403-17.
24. Polychronis A, Sinett HD, Hadjiminas D, et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestreogen receptor positive and epidermal growth factor receptor positive primary breast cancer: a double blind placebo controlled phase II randomized trial. Lancet 2005;6:683-91.
25. Dowsett M, Ebbs SR, Dixon JM, et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen or the combination: influence of hormonal status and HER-2 in breast cancer - a study from the IMPACT trialists. J Clin Oncol 2005;23:2477-92.
26. Miller WR, White S, Dixon JM, Murray J, Renshaw L, Anderson TJ. Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. Br J Cancer 2006;94:1051-6.
27. Christov K, Ikui A, Shilkaitis A, et al. Cell proliferation, apoptosis, and expression of cyclin D1 and cyclin E as potential biomarkers in tamoxifen-treated mammary tumors. Breast Cancer Res Treat 2003;77:253-64.
28. Christov K, Shilkaitis A, Kim ES, Steele V, Lubet R. Chemopreventive agents induce a senescence-like phenotype in rat mammary tumors. Eur J Cancer 2003;39:230-9.
29. Shilkaitis A, Green A, Punj V, Steele VE, Lubet RA, Christov K. DHEA inhibits the progression phase of mammary carcinogenesis by inducing cellular senescence via a p16 dependent but p53 independent mechanism. Breast Cancer Res 2005;7:132-40.
30. Dimri GP, Xinhua L, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995;92:9363-7.
31. Grubbs CJ, Lubet RA, Atigada VR, et al. Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers. Carcinogenesis 2005;27:1232-9.
32. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
33. Christov K, Milev A, Todorov C. DNA aneuploidy and cell proliferation in breast carcinomas. Cancer 1989;64:673-9.
34. Dienstmann R, Bines J. Evidence-based neoadjuvant endocrine therapy for breast cancer. Clin Breast Cancer 2006;7:315-20.
35. Arteaga CL, Baselga J. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. Clin Cancer Res 2003;9:1579-89